| Overview |
| bs-5449R-APC-Cy7 |
| IGF1R (Tyr1165 + Tyr1166) Antibody, APC-Cy7 Conjugated |
| FCM |
| Mouse, Rat |
| Human, Dog, Cow, Pig, Chicken |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human IGF1R around the phosphorylation site of Tyr1165+Tyr1166 |
| Tyr1165 + Tyr1166 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3480 |
| P08069 |
| Cell membrane |
| IGF-1R Tyr1165/Tyr1166; IGF1R phospho Y1165+Y1166; IGF1R phospho Tyr1165+Tyr1166; p-IGF1R Tyr1165+Tyr1166; CD221; CD221 antigen; IGF 1 receptor; IGF 1R; IGF I receptor; IGF1R; IGFIR; IGFIRC; Insulin like growth factor 1 receptor; Insulin like growth factor 1 receptor precursor; JTK13; MGC142170; MGC142172; IGF1 Receptor; IGF1R_HUMAN. |
| This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz